JP5964426B2 - 脂肪酸シンターゼ阻害剤 - Google Patents

脂肪酸シンターゼ阻害剤 Download PDF

Info

Publication number
JP5964426B2
JP5964426B2 JP2014526199A JP2014526199A JP5964426B2 JP 5964426 B2 JP5964426 B2 JP 5964426B2 JP 2014526199 A JP2014526199 A JP 2014526199A JP 2014526199 A JP2014526199 A JP 2014526199A JP 5964426 B2 JP5964426 B2 JP 5964426B2
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
oxo
oxa
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014526199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521748A5 (enExample
JP2014521748A (ja
Inventor
ジョナサン、マイケル、ゲルグロビッチ
マイケル、リー、ムーア
シンシア、アン、パリッシュ
ランス、ハワード、リッジャーズ
ユ、ホンギ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2014521748A publication Critical patent/JP2014521748A/ja
Publication of JP2014521748A5 publication Critical patent/JP2014521748A5/ja
Application granted granted Critical
Publication of JP5964426B2 publication Critical patent/JP5964426B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014526199A 2011-08-19 2012-08-16 脂肪酸シンターゼ阻害剤 Expired - Fee Related JP5964426B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161525402P 2011-08-19 2011-08-19
US61/525,402 2011-08-19
US201261663124P 2012-06-22 2012-06-22
US61/663,124 2012-06-22
PCT/US2012/051064 WO2013028447A1 (en) 2011-08-19 2012-08-16 Fatty acid synthase inhibitors

Publications (3)

Publication Number Publication Date
JP2014521748A JP2014521748A (ja) 2014-08-28
JP2014521748A5 JP2014521748A5 (enExample) 2015-08-06
JP5964426B2 true JP5964426B2 (ja) 2016-08-03

Family

ID=47746768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526199A Expired - Fee Related JP5964426B2 (ja) 2011-08-19 2012-08-16 脂肪酸シンターゼ阻害剤

Country Status (5)

Country Link
US (1) US9084794B2 (enExample)
EP (1) EP2744333B1 (enExample)
JP (1) JP5964426B2 (enExample)
ES (1) ES2608053T3 (enExample)
WO (1) WO2013028447A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014108858A1 (en) 2013-01-10 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Fatty acid synthase inhibitors
JP6616934B2 (ja) * 2014-05-22 2019-12-04 株式会社 資生堂 レナリドミドの光学分割方法
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
PE20180572A1 (es) 2015-06-18 2018-04-04 Cephalon Inc Derivados de piperidina 1,4-sustituidos
EP3310773B1 (en) 2015-06-18 2020-12-02 89Bio Ltd. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
RS59956B1 (sr) 2015-10-23 2020-03-31 Esteve Pharmaceuticals Sa Oksa-diazaspiro jedinjenja koja imaju aktivnost protiv bola
CR20200263A (es) 2017-12-13 2020-07-26 Lupin Ltd Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
EP3636637A1 (en) * 2018-10-10 2020-04-15 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (fasn)
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
WO1997011940A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
WO2001030780A2 (en) * 1999-10-27 2001-05-03 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
JP2006512404A (ja) * 2002-10-22 2006-04-13 グラクソ　グループ　リミテッド Ｈ３受容体リガンドとしてのアリールオキシアルキルアミン誘導体
AU2006230292A1 (en) * 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
PT1961744E (pt) * 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
TW200831092A (en) * 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
JP2013542960A (ja) * 2010-11-08 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 脂肪酸シンターゼ阻害剤

Also Published As

Publication number Publication date
EP2744333B1 (en) 2016-10-05
WO2013028447A1 (en) 2013-02-28
EP2744333A4 (en) 2015-04-22
US9084794B2 (en) 2015-07-21
EP2744333A1 (en) 2014-06-25
ES2608053T3 (es) 2017-04-05
JP2014521748A (ja) 2014-08-28
US20140194415A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
US9084794B2 (en) Fatty acid synthase inhibitors
JP2013542960A (ja) 脂肪酸シンターゼ阻害剤
US8906910B2 (en) Imidazopyridine derivatives as PI3 kinase
US8778937B2 (en) Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
JP2010529031A (ja) Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
JP2010535804A (ja) Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
JP2010539239A (ja) Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
RS55662B1 (sr) Derivati benzimidazola kao inhibitori pi3 kinaze
RS55710B1 (sr) Derivati piridina kao inhibitori kinaze rearanžirane tokom transfekcije (ret)
WO2013028445A1 (en) Fatty acid synthase inhibitors
JP2014515345A (ja) 脂肪酸シンターゼ阻害剤としてのピリミジノン誘導体
WO2018015879A1 (en) Isoquinoline derivatives as perk inhibitors
WO2010120854A1 (en) Chemical compounds
JP2013512245A (ja) 脂肪酸合成酵素阻害剤としてのアザベンズイミダゾール
JP2009533467A (ja) Ｐｉ３キナーゼ阻害剤としてのチアゾリジンジオン誘導体
JP2014508097A (ja) 脂肪酸合成酵素阻害剤
EP2493310A1 (en) Benzimidazoles as fatty acid synthase inhibitors
JP2019516759A (ja) がんの処置のためのピラゾロピリジン誘導体
AU2014321456B2 (en) Combination drug therapy
JP6231129B2 (ja) 脂肪酸シンターゼ阻害剤
WO2013052716A1 (en) Fatty acid synthase inhibitors
JP2012527471A (ja) Ｐｉ３キナーゼ阻害剤としてのチアゾロピリミジノン誘導体
WO2013096153A1 (en) Chemical compounds
WO2014008223A2 (en) Fatty acid synthase inhibitors
WO2013177253A2 (en) Fatty acid synthase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150618

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160603

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160629

R150 Certificate of patent or registration of utility model

Ref document number: 5964426

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees